NEW YORK (TheStreet) -- Shares of Eli Lilly and Co (LLY) - Get Report  are up 1.37% to $83.10 in pre-market trading on Tuesday after the Indianapolis-based pharmaceutical giant posted mixed fiscal 2016 second quarter results before today's market open.

The company posted earnings of 86 cents per share on revenue of $5.4 billion, compared to analysts projected earnings of 86 cents per share on revenue of $5.15 billion. Revenue increased 9% year-over-year.

Last year, Lilly reported second quarter earnings of 90 cents per share on revenue of $4.98 billion. 

The company expects full-year earnings to be in the range of $3.50 to $3.60 and revenue to be $20.6 billion to $21.1 billion. 

This quarter, the company saw increased demand for its drugs including Trulicity, Cyramza and Humalog, CNBC reports. A large part of the company's recent volume growth is a result of new products launched, said Lilly CEO John Lechleiter, according to CNBC. 

Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:

We rate LILLY (ELI) & CO as a Buy with a ratings score of B. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow.

You can view the full analysis from the report here: LLY

Image placeholder title

LLY

data by

YCharts